Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
Status:
Completed
Trial end date:
2017-03-27
Target enrollment:
Participant gender:
Summary
This multicenter, phase II, open label study will enroll patients with chronic cold
agglutinin disorder. A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv
on days 1, 4, 8, 11.